A5037960337- Head and Neck Cancer Studies
- Viral-associated cancers and disorders
- Lymphoma Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Esophageal and GI Pathology
- Dysphagia Assessment and Management
- Immunotherapy and Immune Responses
- Medical Imaging Techniques and Applications
- vaccines and immunoinformatics approaches
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Head and Neck Surgical Oncology
- Lung Cancer Research Studies
- Parvovirus B19 Infection Studies
- Oral and Maxillofacial Pathology
- Cancer Genomics and Diagnostics
- Counseling Practices and Supervision
- Inflammatory Biomarkers in Disease Prognosis
- Cancer Diagnosis and Treatment
- Radiation Therapy and Dosimetry
- Metastasis and carcinoma case studies
- Radiomics and Machine Learning in Medical Imaging
- Advances in Oncology and Radiotherapy
- Brain Metastases and Treatment
The Christie NHS Foundation Trust
2011-2024
Abstract Purpose: Epstein–Barr virus (EBV) is associated with several cancers in which the tumor cells express EBV antigens EBNA1 and LMP2. A therapeutic vaccine comprising a recombinant vaccinia virus, MVA-EL, was designed to boost immunity these antigens. phase I trial conducted demonstrate safety immunogenicity of MVA-EL across range doses. Experimental Design: Sixteen patients United Kingdom (UK) EBV-positive nasopharyngeal carcinoma (NPC) received three intradermal vaccinations at...
There is a need to refine the selection of patients with oropharyngeal squamous cell carcinoma (OPSCC) for treatment de-escalation. We investigated whether pretreatment absolute lymphocyte count (ALC) predicted overall survival (OS) benefit from addition concurrent chemotherapy radical radiotherapy.
Purpose Dysphagia is a common toxicity after head and neck (HN) radiotherapy that negatively affects quality of life. We explored the relationship between dose to normal HN structures dysphagia one year treatment using image-based datamining (IBDM), voxel-based analysis technique. Materials Methods used data from 104 oropharyngeal cancer patients treated with definitive (Chemo)RT. Swallow function was assessed pre-treatment 1 three validated measures: M.D. Anderson Inventory (MDADI),...
The aim of this study was to report outcomes and late toxicity following hypofractionated accelerated radiotherapy for T2 glottic cancers. We highlight the importance treatments with shorter overall treatment times, in improving also compare biologically effective dose regimes, conventional fractionation. One hundred twelve patients cancer were treated between January 1999 December 2005. All prescribed a 52.5 Gray 3.28 per fraction, delivered over 22 days. Radiobiological calculations used...
To evaluate dosimetric consequences of inter-fraction setup variation and anatomical changes in patients receiving multifield optimised (MFO) intensity modulated proton therapy for post-operative oropharyngeal (OPC) oral cavity (OCC) cancers.
<p>Additional detail of materials and methods used. Figure 1. Flow chart detailing dose escalation schema. 2. MVA-EBNA1/LMP2 Vaccination does not alter broad subsets immune cells. 3. EBNA1 antibody response before after MVA-EL vaccination. Table 1 MHC class I II restricted epitope peptides in LMP2 used as targets ELIspot assays. 2 Summary EBNA1- LMP2-specific responses stimulated by vaccination UK NPC patients.</p>
<div>Abstract<p><b>Purpose:</b> Epstein–Barr virus (EBV) is associated with several cancers in which the tumor cells express EBV antigens EBNA1 and LMP2. A therapeutic vaccine comprising a recombinant vaccinia virus, MVA-EL, was designed to boost immunity these antigens. phase I trial conducted demonstrate safety immunogenicity of MVA-EL across range doses.</p><p><b>Experimental Design:</b> Sixteen patients United Kingdom (UK) EBV-positive...
<div>Abstract<p><b>Purpose:</b> Epstein–Barr virus (EBV) is associated with several cancers in which the tumor cells express EBV antigens EBNA1 and LMP2. A therapeutic vaccine comprising a recombinant vaccinia virus, MVA-EL, was designed to boost immunity these antigens. phase I trial conducted demonstrate safety immunogenicity of MVA-EL across range doses.</p><p><b>Experimental Design:</b> Sixteen patients United Kingdom (UK) EBV-positive...
<p>Additional detail of materials and methods used. Figure 1. Flow chart detailing dose escalation schema. 2. MVA-EBNA1/LMP2 Vaccination does not alter broad subsets immune cells. 3. EBNA1 antibody response before after MVA-EL vaccination. Table 1 MHC class I II restricted epitope peptides in LMP2 used as targets ELIspot assays. 2 Summary EBNA1- LMP2-specific responses stimulated by vaccination UK NPC patients.</p>
Sarcomatoid carcinoma is a rare clinical entity, especially when presenting in the nasopharynx. We describe first documented case of nasopharyngeal sarcomatoid with intracranial extension 59-year-old Caucasian man severe bifrontal headache and diplopia, secondary to left abducens nerve palsy. highlight some major diagnostic challenges its unusual histological appearance. outline importance multidisciplinary approach his management, which includes input from medicine, neurosurgery, Ear, Nose...
Purpose: Tumor and target volume manual delineation remains a challenging task in head neck cancer radiotherapy. The purpose of this study is to conduct multi-institutional evaluation delineations gross tumor (GTV), high-risk clinical (CTV), parotids, submandibular glands on treatment simulation MR scans oropharyngeal (OPC) patients. Methods: Pre-treatment T1-weighted (T1w), with Gadolinium contrast (T1w+C) T2-weighted (T2w) MRI were retrospectively collected for 4 OPC patients under an...